Плевральный выпот при раке легкого

1. Акопов А.Л., Кондратьев В.Б. Лечение метастатических опухолевых экссудативных плевритов внутриполостным введением блеомицина. Вопр. онкол. 1999; 4: 411—415.

2. Журавлев А.В. К вопросу о двусторонних плевральных выпотах. В кн.: Проблемы терапевтической и хирургической пульмонологи. СПб.; 1997. 216—217.

3. Журавлев А.В., Доброборская Т.Н., Чернякова Д.Н. Повышенное содержание амилазы в плевральных выпотах опухолевой природы. Пробл. туб. 1998; 5: 65—66.

4. Садовников А.А., Панченко К.И. Мезотелиома плевры. Грудная и серд.-сосуд. хир. 1998; 4: 48—53.

5. Сыроватко А.С. Пункционная биопсия плевры при плевритах неясной этиологии. Пробл. туб. 1998; 5: 60—61.

6. Трубников Г.А., Уклистая Т.А. Маркеры воспаления и опухолей в диагностике природы серозного плеврального выпота. Клин. мед. 1997; 6: 15—20.

7. Фоминых И.В., Коваленко B.JI. Морфологические аспекты прижизненной верификации опухолевых поражений плевры. Арх. пат. 1998; 4: 71—74.

8. Чучалин А.Г. Плевра: патофизиологические и клинические аспекты. Пульмонология 1999; 1: 6—10.

9. Юдин Л.А., Королева И.М. Компьютерная томография плевры. Вестн. рентгенол. и радиол. 1997; 2: 11—15.

10. Aelony Y., King R., Boutin С. Thoracoscopic talc powder for chronic reccurent pleural effusion. Ann. Intern. Med. 1991; 115: 778—782.

11. Assi Z., Caruso J.L., Herndon J., Patz E.F. Cytologically proved malignant pleural effusions: distribution of transudates and exudates. Chest 1998; 113: 1302—1304.

12. Atagi S., Ogawara М., Kawahara M. et al. Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: likelihood ratios for malignant mesothelioma. Jpn. J. Clin. Oncol. 1997; 27: 293—297.

13. Brinkman G.L. The significance of pleural effusion complicating otherwise operable bronchogenic carcinoma. Dis. Chest 1959; 36: 152—155.

14. Buchmann I., Guhlmann C.A., Eisner K. et al. F-18-FDG PET for primary diagnosis of pleural processes. Nuklearmedizin 1999; 38: 319—322.

15. Canto A., Ferref G., Romagosa V. et al. Lung cancer and pleural effusion: Clinical significance and study of pleural metastatic locations. Chest 1985; 87: 649—655.

16. Canto A., ArnauA., Galbis J. et al. The so-called malignant pleural effusion: a new review of direct data obtained with diagnostic pleuroscopy. Arch. Bronchopneumol. 1996; 32: 453—458.

17. Casali A., Gionfra Т., Rinaldi M. et al. Treatment of malignant pleural effusion with intracavitary Corinabacterium parvum. Thorax 1985; 40: 515.

18. Chen N.H., Hsieh I. C.,- Tsao T.C. Comparison of the clinical diagnostic value between pleural needle biopsy and analysis of pleural effusion. Chang Keng I Hsueh 1997; 20: 11—16.

19. Cheng D., Rodriguez R.M., Perkett E. A. et at. Vascular endothelial growth factor in pleural fluid. Chest 1999; 116: 760—765.

20. Chernow B., Sahin S.A. Carcinomatous involvement of the pleura: an analysis of 96 patients. Am. J. Med. 1977; 63: 695—699.

21. Danby C.A., Adebonojo S.A., Moritz D.M. Video-assisted talc pleurodesis for malignant pleural effusions utilizing local anesthesia and 1. V. sedation. Chest 1998; 113: 739—742.

22. Decker D.A., Dines D.E., Payne U7.S. et at. The significance of a cytologically negative pleural effusion in bronchogenic carcinoma. Ibid. 1978; 74: 640—646.

23. Fujita A., Takabatake Ii., Tagaki S., Sekine K. Efficacy of systemic chemotherapy in adenocarcinoma of the lung with pleuritis carcinomatosa. Gan To Kagaku Ryoho 1997; 24: 1987—1991.

24. Gorg C., Restrepo I., Schwerk W.B. Sonography of malignant pleural effusion. Eur. Radiol. 1997; 7: 1195—1198.

25. Jancovici R., Lang-Lazdunski L., Pons F., Cador L. Complications of video-assisted thoracic surgery: a five-year experience. Ann. Thorac. Surg. 1996; 61: 533—537.

26. Kashiwabara K., Nakamura H., Esaki T. Serum cytokeratin 19 fragment levels in non-small cell lung cancer patients according to T factor in the TNM classification. Clin. Chim. Acta 1999; 288: 153—159.

27. Kramer M.R., Saldana M.J., Cepero R.J. et al. High amylase levels in neoplasm-related pleural effusion. Ann. Intern. Med. 1989; 110: 567-572.

28. Landreneau R.J., Mack M. J., Dowling R. D. et al. The role of thoracoscopy in lung cancer management. Chest 1998; 113: 6S-12S.

29. Martinez-Moragon E., Aparicio J., Rogado M.C. et al. Pleurodesis in malignant pleural effusion: a randomized study of tetracycline versus bleomycin. Eur. Resp. J. 1997; 10: 2380-2383.

30. Masotti A., Fumagalli L., Morandini G.C. Intrapleural administration of recombinant interleukin-2 in non-small cell lung cancer with neoplastic pleural effusion. Monaldi Arch. Chest Dis. 1997; 52: 225—228.

31. McLeod D.T., Calverley P.M., Millar J.W. Further experience of Corinebacterium parvurn in malignant pleural effusions. Thorax 1985; 40: 515—516.

32. Meyer P.C. Metastatic carcinoma of the pleura. Ibid. 437—454.

33. Miedouge M.. Rouzaud P., Salama G. et al. Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions. Br. J. Cancer 1999; 81: 1059—1065.

34. Monte S.A., Ehya II., Lang W. Positive effusion cytology as a initial presentation of malignancy. Acta Cytol. 1987; 31: 448—452.

35. Naito T., Satoh H., Ishikawa LI. et al. Pleural effusion as a significant prognostic factor in non-small cell lung cancer. Anticancer Res. 1997; 17: 4743—4746.

36. Nio Y., Nagami H., Tamura K. et al. Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion. Br. J. Cancer 1999; 80: 775—785.

37. Patz E.F., McAdams LI.P., Erasmus J.J. et al. Sclerotherapy for malignant pleural effusion: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage. Chest 1998; 113: 1305—1311.

38. Perng R.P., Chen Y.M., Wu M.F. et al. Phase II trial of intrapleural paclitaxel injection for non-small-cell lung cancer patients with malignant pleural effusions. Respir. Med. 1998; 92: 473—479.

39. Romero S., Feernandez C., Arriero J.M. et al. CEA, CA 15—3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions. Eur. Respir. J. 1996; 9: 17—23.

40. Ruckdeschel J.C., Moores D., Lee J.Y. et al. Intrapleural therapy for malignant pleural effusions: A randomized comparison of bleomycin and tetracyclin. Chest 1991; 100: 528—531.

41. Sahn S.A., Good T. Pleural fluid pH in malignant effusions: Diagnostic, prognostic and therapeutic implications. Ann. Intern. Med. 1988; 108: 345—350.

42. Sahn S.A. Malignancy metastatic to the pleura. Clin. Chest Med. 1998; 19: 351—361.

43. Salyer W.A., Eggleston J.C., Erosan Y.S. Efficacy of pleural needle biopsy and pleural fluid cytopathology in the diagnosis of malignant neoplasm involving the pleura. Chest 1975; 67: 536—540.

44. Sanchez de Cos Escuin J., Lopez Parra S., Disdier Vicente C. et al. Diagnostic utility of carcinoembryonic antigen, neuron-specific enolase and squamous cell carcinoma antigen in malignant pleural effusion. An. Med. Interna 1996; 13: 369—373.

45. Stoetzer O.J., Munker R., Darsow М., Wilmanns W. P53-immunoreactive cells in benign and malignant effusions: diagnostic value using a panel of monoclonal antibodies and comparison with CEA-staining. Oncol. Rep. 1999; 6: 455—458.

46. Tanaka A., Sato T. Adhesion therapy for malignant pleural effusion (intrapleural administration of OK-432 with minocycline). Nippon Kokyuki Gakkai Zasshi 1999; 37: 531—537.

47. Tohcla Y., Iwanaga T., Takada M. et al. Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer. Chemotherapy 1999; 45: 197—204.

48. Toumbis М., Rasidakis A., Passalidou E. et al. Evaluation of CYFRA 21-1 in malignant and benign pleural effusions. Anticancer Res. 1996; 16: 2101—2104.

49. van de Molengraft F.J., Vooijs G.P. The interval between the diagnosis of malignancy and the development of effusion, with reference to the role of cytologic diagnosis. Acta Cytol. 1988; 32: 183—186.

50. Vargas F.S., Teixeira L.R. Pleural malignancies. Curr. Opin. Pulm. Med. 1996; 2: 335—340.

51. Wada I., Yokouchi М., Saitoh H. et al. Pharmacokinetics of etoposide after intrathoracic instillation to lung cancer patients with pleural effusion. Int. J. Clin. Pharmacol. Ther. 1999; 37: 254—259.

52. Yamaguchi E., Nagai A., Sakamoto K., Takizawa T. Morphological changes in the pleura caused by intracavitary administration of bleomycin. Gan To Kagaku Ryoho 1991; 18: 971—975.

53. Yamamoto A., Shimizu E., Sumitomo K. et al. L-Мус overexpression and detection of auto-antibodies against L-Мус in both the serum and pleural effusion from a patient with non-small cell lung cancer. J. Intern. Med. 1997; 36: 724—727.

54. Yanagawa H., Takeuchi E., Suzuki Y. et al. Presence and potent immunosuppressive role of interleukin-10 in malignant pleural effusion due to lung cancer. Cancer Lett. 1999; 8: 27—32.

55. Yokoi K., Miyazawa N. Pleuropneumonectomy and postoperative adjuvant chemotherapy for carcinomatous pleuritis in primary lung cancer: a case report of long-term survi